Original from: 360dx
The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.
The agreement includes the development of a cartridge-based point-of-care instrument that can be used to aid the diagnosis of cancers and other diseases.
Under the terms of the agreement, Dongwoon Anatech will provide up to $787,500 annually to support research led by David Wong, director of the UCLA Center for Oral/Head & Neck Oncology Research, who is leading the development of a proprietary liquid biopsy platform. Wong's team has been developing its Electric Field-Induced Release and Measurement (EFIRM) liquid biopsy platform that uses electric fields for the measurement of extracellular vesicles and other biomarkers, and UCLA said that his team has shown that the technology can be used to identify tumor-specific mutations in a saliva sample, especially mutations for non-small cell lung cancer.
The university said that results so far show that the testing methods perform with high sensitivity and specificity. It also noted that the US National Institutes of Health and other agencies have provided more than $29 million in funding to support EFIRM research and development since 2002.
UCLA said that the collaboration will begin with the optimization of protocols for Dongwoon Anatech's D-SaLife saliva-based glucose monitoring system using clinical samples from patients in the US and South Korea. The later phases of the project will involve the development and validation of the EFIRM I fully automated testing instrument for the detection of saliva-based biomarkers of lung, gastric, and oral cancers, among others.
The partners also intend to co-develop the successor EFIRM II point-of-care instrument, which will be a cartridge-based platform that is designed for scalable manufacturing.
Source: UCLA, Dongwoon Anatech Form Collaboration on Saliva-Based Diagnostic Testing
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.